Valuation
- Market cap
- 8,422,000
- Revenue TTM
- $320,000
- Net income TTM
- $-10,260,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -3,206.25%
- Debt to equity
- 0.05
Trading
- Volume
- 35,000
- Avg volume
- 15,956
- Day's range
- $1.20 – $1.43
- Shares out
- 7,018,000
- Stochastic %K
- 0%
- Beta
- 1.51
- Analysts
- Strong Buy
- Price target
- $8.83
Company profile
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treat...
Show more
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 973 832 8147
- Website
- https://www.vyometx.com
- Address
- Harvard Square, One Mifflin Place Suite 400, Cambridge, United States
Latest news
No headlines yet.